Photo by jmvisuals from unsplash
ABSTRACT Introduction Clostridiodes difficile infection (CDI) is a life-threatening illness that has been labelled as an urgent threat by the Centers for Disease prevention (CDC). Areas Covered RBX2660, a live… Click to show full abstract
ABSTRACT Introduction Clostridiodes difficile infection (CDI) is a life-threatening illness that has been labelled as an urgent threat by the Centers for Disease prevention (CDC). Areas Covered RBX2660, a live biotherapeutic product offers a very promising treatment option for patients with recurrent Clostridiodes difficile infection(rCDI). RBX2660 restores the healthy gut microbiome and shows clinically meaningful benefits for patients suffering from rCDI. Safety, efficacy, and tolerability of RBX2660 have been thoroughly assessed . Expert Opinion An FDA-approved, standardized, and accessible microbiota restoration product like RBX2660 would provide a new option for patients in need of treatment for rCDI by breaking the cycle of disease recurrence.
Journal Title: Expert Review of Anti-infective Therapy
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!